PLA may have been developing corona variants under the cover of developing antibody

Recently, the team of Academician Zhi-Nan Chen of the Air Force Military Medical University (空军军医大学) of Chinese People's Liberation Army and Jiangsu Pacific Meniuoke Biopharmaceutical Co., Ltd江苏太平洋美诺克生物药业有限公司 jointly developed the original new drug "Mepolizumab for Injection" of specific receptor blocking antibody against COVID-19. After pharmaceutical research, Phase I, Phase II, and Phase III clinical trials, it has been approved for clinical application. Since the first batch of medical teams went to Wuhan on Lunar New Year's Eve in 2020, Academician Zhi-Nan Chen of the Air Force Military Medical University has led a joint research team composed of relevant experts from the National Center for Molecular Medicine Transformation, School of Basic Medicine, Xijing Hospital, and Tangdu Hospital to deploy tackling key problems on anti-COVID-19 drugs .